Graft-versus-leukaemia effect in children:: chronic GVHD has a significant impact on relapse and survival

被引:47
作者
Jernberg, ÅG
Remberger, M
Ringdén, O
Winiarski, J
机构
[1] Huddinge Univ Hosp, Karolinska Inst, Dept Paediat, S-14186 Huddinge, Sweden
[2] Huddinge Univ Hosp, Karolinska Inst, Dept Clin Immunol, S-14186 Huddinge, Sweden
[3] Huddinge Univ Hosp, Karolinska Inst, Ctr Allogene Stem Cell Transplantat, S-14186 Huddinge, Sweden
关键词
bone marrow transplantation; children graft-versus-host disease; graft-versus-leukaemia; relapse survival;
D O I
10.1038/sj.bmt.1703808
中图分类号
Q6 [生物物理学];
学科分类号
071011 ;
摘要
To examine whether graft-versus-host-disease (GVHD) is associated with a graft-versus-leukaemia (GVL) effect that also influences the outcome of allogeneic stem cell transplantation (SCT) in childhood acute leukaemia, we evaluated all consecutive (n = 169) children who had undergone SCT for ALL and AML at our centre. Median follow-up was 7 years. The 5-year probability of chronic GVHD was 34%. Median time to relapse was 24 months in children with chronic GVHD and 6 months in those without. The corresponding 5-year probabilities of relapse were 30 and 45% (P=0.01). The 5-year probability of survival was 54%. Patients with chronic GVHD had a significantly better survival, 77 vs 51% (P = 0.01). In a Cox regression model, chronic GVHD independently decreased the risk of relapse (RR 0.44) and further predicted an increased chance of relapse-free survival (RR 1.7) and survival (RR 2.6). The impact of chronic GVHD on survival was most apparent in late-stage disease and in ALL. Acute GVHD was not an independent predictor for relapse or death in this study. This study is in support of a GVL effect in childhood leukaemia related to chronic GVHD, reducing the risk of relapse and improving survival.
引用
收藏
页码:175 / 181
页数:7
相关论文
共 39 条
[1]   PROSPECTIVE COMPARATIVE-STUDY OF BONE-MARROW TRANSPLANTATION AND POSTREMISSION CHEMOTHERAPY FOR CHILDHOOD ACUTE MYELOGENOUS LEUKEMIA [J].
AMADORI, S ;
TESTI, AM ;
ARICO, M ;
COMELLI, A ;
GIULIANO, M ;
MADON, E ;
MASERA, G ;
RONDELLI, R ;
ZANESCO, L ;
MANDELLI, F .
JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (06) :1046-1054
[2]  
BALDUZZI A, 1995, BLOOD, V86, P3247
[3]   TREATMENT OF MURINE LEUKAEMIA WITH X-RAYS AND HOMOLOGOUS BONE MARROW .2. [J].
BARNES, DWH ;
LOUTIT, JF .
BRITISH JOURNAL OF HAEMATOLOGY, 1957, 3 (03) :241-252
[4]   BONE-MARROW TRANSPLANTS FROM HLA-IDENTICAL SIBLINGS AS COMPARED WITH CHEMOTHERAPY FOR CHILDREN WITH ACUTE LYMPHOBLASTIC-LEUKEMIA IN A 2ND REMISSION [J].
BARRETT, AJ ;
HOROWITZ, MM ;
POLLOCK, BH ;
ZHANG, MJ ;
BORTIN, MM ;
BUCHANAN, GR ;
CAMITTA, BM ;
OCHS, J ;
GRAHAMPOLE, J ;
ROWLINGS, PA ;
RIMM, AA ;
KLEIN, JP ;
SHUSTER, JJ ;
SOBOCINSKI, KA ;
GALE, RP .
NEW ENGLAND JOURNAL OF MEDICINE, 1994, 331 (19) :1253-1258
[5]   Risk factors for chronic graft-versus-host disease after bone marrow transplantation:: a retrospective single centre analysis [J].
Carlens, S ;
Ringdén, O ;
Remberger, M ;
Lönnqvist, B ;
Hägglund, H ;
Klaesson, S ;
Mattsson, J ;
Svahn, BM ;
Winiarski, J ;
Ljungman, P ;
Aschan, J .
BONE MARROW TRANSPLANTATION, 1998, 22 (08) :755-761
[6]   Immunobiology -: TCRγδ cytotoxic T lymphocytes expressing the killer cell-inhibitory receptor p58.2 (CD158b) selectively lyse acute myeloid leukemia cells [J].
Dolstra, H ;
Fredrix, H ;
van der Meer, A ;
de Witte, T ;
Figdor, C ;
van de Wiel-van Kemenade, E .
BONE MARROW TRANSPLANTATION, 2001, 27 (10) :1087-1093
[7]  
DONEY K, 1991, BONE MARROW TRANSPL, V7, P453
[8]  
EISNER MD, 1995, BONE MARROW TRANSPL, V15, P663
[9]   Th2 and Tc2 cells in the regulation of GVHD, GVL, and graft rejection: Considerations for the allogeneic transplantation therapy of leukemia and lymphoma [J].
Fowler, DH ;
Gress, RE .
LEUKEMIA & LYMPHOMA, 2000, 38 (3-4) :221-234
[10]   CLINICAL MANIFESTATIONS OF GRAFT VERSUS HOST DISEASE IN HUMAN RECIPIENTS OF MARROW FROM HL-A-MATCHED SIBLING DONORS [J].
GLUCKSBERG, H ;
STORB, R ;
FEFER, A ;
BUCKNER, CD ;
NEIMAN, PE ;
CLIFT, RA ;
LERNER, KG ;
THOMAS, ED .
TRANSPLANTATION, 1974, 18 (04) :295-304